Singapore Therapeutics Development Review (STDR) 2026 (Jul)
The Singapore Therapeutics Development Review 2026 (Jul) by A*STAR funds and mentors public sector research to accelerate innovative therapeutics and biotech development in Singapore.
Funder: Agency for Science Technology and Research
Due Dates: August 27, 2026 (Submission deadline for Pre-Pilot and Pilot proposals)
Funding Amounts: Pre-Pilot: up to S$325K/project (1 year); Pilot: up to S$1M/project (2 years, phased)
Summary: Supports Singapore public sector researchers in drug discovery and biotech development with phased funding, mentorship, and commercialization guidance.
Key Information: Applications must be submitted via iGrants and endorsed by institutional offices by the deadline.
Description
The Singapore Therapeutics Development Review (STDR) 2026 (Jul) grant is a national initiative led by the Agency for Science Technology and Research (A*STAR), in partnership with EDDC, NATi, and SMART. It aims to accelerate the translation of innovative therapeutic concepts from Singapore’s public research sector into commercially viable products. The grant provides phased funding, active project management, mentoring from industry leaders, specialized bootcamps, and networking opportunities to strengthen Singapore’s drug development and biotech pipeline. The program is modality-agnostic, supporting small molecules, biologics, cell and gene therapies, and platform technologies at both early proof-of-concept (Pre-Pilot) and more advanced (Pilot) stages.
